Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase IV
Latest Information Update: 03 May 2019
Price : $35 *
At a glance
- Drugs Rengalin (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Materia Medica Holdings
- 30 Apr 2019 Status changed from recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
- 09 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Jun 2019.